Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
Imidapril is hydrolysed to the active metabolite imidaprilat, which competitively inhibits angiotensin-converting enzyme. This reduces angiotensin II formation and aldosterone secretion, lowers peripheral vascular resistance and blood pressure, and reduces sodium and water retention.
Indications / reported uses
Treatment of essential hypertension.
Use in selected patients with chronic heart failure or diabetic nephropathy has been described in clinical studies and depends on local product authorisation.
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Imidapril PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Imidapril Permitted Daily Exposure (PDE) report (the Imidapril PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Imidapril Occupational Exposure Limit (OEL) report (the Imidapril OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.